A new phase 1 trial demonstrates the safety and effectiveness of personalized neoantigen DNA vaccines, showing promising ...

Our study found that doing these kinds of screenings on patients doesn't make any marked difference in their long-term survival rates." J. Brent Muhlestein, principal investigator of the study and ...

LONDON, UK I 14, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive headline results from a planned interim analysis of the DREAMM-7 ...

Discover reliable and free data sources to enhance your SEO content strategy. Build authority and credibility with accurate and trustworthy data. The internet is awash in an endless stream of ...

Here's why it made the list ...

Reducing the risk of metastatic relapse in patients with resectable soft tissue sarcomas is crucial for improving outcomes, because metastasis is the primary cause of mortality in this population.

The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically changed in recent years.

The N-AVD regimen showed improved progression-free survival and lower toxicity than BV-AVD in advanced Hodgkin lymphoma, ...